OCUL · Ocular Therapeutix, Inc.
$6.50
-1.66% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-4.4
Dividend yield
0.0%
Beta
0.99
Avg volume
3M
Employees
0K
Daily Change %
-1.66%
5 Days Change
-3.78%
10 Days Change
-8.70%
30 Days Change
-33.90%
60 Days Change
-38.68%
Month to Day Change
-9.33%
Year to Day Change
-45.55%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OCUL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-19
Latest call per bank · past 12 months
UBS
Buy$14.00
+115.4% vs priceRBC Capital
Outperform$30.00
+361.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Needham | Reiterates | Buy | $18.00 |
| 2026-10-12 | UBS | Initiates | Buy | $0.00 → $14.00 |
| 2026-10-02 | Chardan Capital | Maintains | Buy | $23.00 |
| 2026-09-29 | Needham | Reiterates | Buy | $18.00 |
| 2026-09-16 | Chardan Capital | Maintains | Buy | $23.00 |
| 2026-09-16 | HC Wainwright & Co. | Reiterates | Buy | $25.00 |
| 2026-08-04 | Chardan Capital | Maintains | Buy | $23.00 |
| 2026-06-25 | Chardan Capital | Maintains | Buy | $21.00 → $23.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 33 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 29.4% below the 50-day MA ($9.21).
- bearish: Price vs 200-day MA: Trading 29.5% below the 200-day MA ($9.22).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.00) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($6.29).
OCUL Price Chart
Loading chart for OCUL…
Fundamentals
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.